Researchers have made a significant advancement in understanding Alzheimer’s disease by exploring how the brain manages cholesterol transport. Rafael Holdings, through its subsidiary Cyclo Therapeutics, has secured an exclusive licensing agreement with MIT for a patent that focuses on small molecules aimed at improving myelination in individuals with the ApoE4 gene variant, a major genetic risk factor for Alzheimer’s. This approach suggests that Alzheimer’s progression may not only be due to toxic protein buildup but also to how effectively the brain distributes essential materials like cholesterol.

This discovery is particularly relevant for people concerned about cognitive health as they age. The ApoE4 variant is found in 50–70% of Alzheimer’s patients and is linked to earlier onset of the disease. By improving cholesterol transport in the brain, the investigational compound Trappsol Cyclo may help maintain cognitive function, enhance learning and memory, and reduce tau pathology, which is associated with Alzheimer’s. This means that targeting cholesterol transport could be a promising avenue for preventing or slowing cognitive decline in those at risk.

Currently, the research is in the early stages, with preclinical data showing potential benefits in mice. While this is promising, it is important to note that these findings have not yet been proven in humans. The focus on specific genetic subgroups like those with the ApoE4 variant represents a shift towards precision medicine in treating Alzheimer’s, moving away from one-size-fits-all solutions. This could lay the groundwork for broader applications of cyclodextrin therapies in other neurological conditions.

As this research progresses, it may be worthwhile to stay informed about developments in cholesterol management and brain health, particularly for those with a family history of Alzheimer’s or cognitive decline.

Source: longevity.technology